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5 cc. & 10 cc. Concentrated Anti-Pneumococcus Serum (Type I)
5 cc. & 10 cc. Concentrated Anti-Pneumococcus Serum (Type II)
Should there be occasion to administer serum prior to receipt of a
report of the typing of a case, a physician may mix these sera.
U
ntil recently the use of an unconcentrated serum for type I infec
tions represented the only serum treatment for pneumonia which
had gained general recognition. While this serum did not affect Type II,
Type III or Group IV cases, it proved to be a very effective therapeutic agent
in Type I cases in which it was used intravenously in large doses.
The obvious difficulties attendant upon the use of large doses of
unconcentrated anti-pneumococcus serum have been greatly reduced, Felton
and other having succeeded in evolving not only an effective highly con-
centrated Type I serum but also a corresponding Type II serum. This
achievement is of very real significance, since Type I or Type II pneumo-
cocci are the causative agents in over fifty per cent of all cases of lobar
pneumonia.
Promising results have been obtained from the intravenous use of con-
centrated anti-pneumococcus sera prepared in the Connaught Laboratories,
and supplies of these sera are now being made available in four containers
as follows:
In the 19th century, it was discovered that immune sera were useful in treating
 infectious diseases. Serum therapy was largely abandoned in the 1940s because of the
toxicity associated with the administration of heterologous sera and the introduction of
effective antimicrobial chemotherapy. Recent advances in the technology of monoclonal
antibody production provide the means to generate human antibody reagents and
reintroduce antibody therapies, while avoiding the toxicities associated with serum
therapy. Because of the versatility of antibodies, antibody-based therapies could, in
theory, be developed against any existing pathogen. The advantages of antibody-based
therapies include versatility, low toxicity, pathogen specificity, enhancement of immune
function, and favorable pharmacokinetics; the disadvantages include high cost, limited
usefulness against mixed infections, and the need for early and precise microbiologic
diagnosis. The potential of antibodies as antiinfective agents has not been fully tapped.
Antibody-based therapies constitute a potentially useful option against newly emergent
pathogens.
In the mid-1990s, successful implementation of
antiinfective therapy has become increasingly diffi-
cult because of widespread antimicrobial resistance,
the emergence of new pathogens, and the occurrence
of many infections in immunocompromised patients
in whom antimicrobial drugs are less effective.
Infections caused by some new pathogens
(e.g., human immunodefficiency virus [HIV] and
Cryptosporidium parvum) cannot be cured with ex-
isting antimicrobial drugs. Regaining the upper
hand in the struggle against microbes requires
multidisciplinary efforts which include developing
new antimicrobial agents (1), improving surveillance
for emerging microbial threats (2), teaching the cor-
rect use of antimicrobial therapy (3), expanding the
use of vaccines to prevent infection (4), developing
adjunctive immunotherapies (5), and conducting
new basic research on the mechanisms of pathogen-
esis and drug resistance. In this article, the potential
of antibody therapy in confronting the threat of
emergent infections will be explored.
Antibody-Based Therapies: Then and Now
Antibody-based (serum) therapies were first used
to treat human infections in the 1890s (6,7). In the
early 20th century, serum  therapy was used to treat
a variety of bacterial infections, including
those cased by Corynebacterium diphtheriae,  Strep-
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Figure 1. Advertisement for type-specific anti-pneumo-
coccal sera from the March 1931 issue of the Canadian
Medical Association Journal. The text in this advertise-
ment describes advancements in the preparation of
antibody solutions and emphasizes the need for using
type-specific serum in the therapy of pneumococcal pneu-
monia. Note the suggestion that type-specific serum can
be mixed for empiric therapy of pneumonia. (Reprinted
with permission.)
Prices and information regarding the use of Type I
and Type II concentrated Anti-Pneumococcus Sera
will be gladly supplied upon request.Vol. 2, No. 3—July-September 1996 Emerging Infectious Diseases 201
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tococcus pneumoniae, Neisseria meningitides,
Haemophilus influenzae, group A streptococcus, and
Clostridium tetani (6,7). By the 1930s, serum
therapy was standard treatment for lobar pneumo-
nia (Figure 1). Several large controlled trials showed
that administering type-specific serum reduced the
death rate in patients with pneumococcal pneumo-
nia by approximately 50% (6). However, when
antimicrobial chemotherapy was discovered in the
mid-1930s, serum therapy for bacterial infections
was rapidly abandoned. Antimicrobial chemotherapy
had important advantages over serum therapy: it
was more effective and less toxic. The immediate
side effects of serum therapy included fevers, chills,
and allergic reactions (8,9). A delayed toxic reaction
of serum therapy was “serum sickness,” a syndrome
characterized by rash, proteinuria, and arthralgia;
this occurred in 10% to 50% of patients who received
heterologous serum and was probably caused by
immune complexes. Other disadvantages of serum
therapy included the need to establish a precise di-
agnosis before selecting serum, lot-to-lot variation
of serum, and the need for considerable physician
expertise (Table 1). Serum therapy could fail because
of inadequate dosage, delayed treatment, mis-label-
ing of serum, and because the infection was mixed
or complicated (i.e., empyema) (10). Producing thera-
peutic sera was very expensive because of the costs
of animal husbandry, antibody purification, refrig-
eration, and standardization by the mouse protection
tests. When antimicrobial chemotherapy was first
introduced, enthusiasm was expressed for combin-
ing serum therapy and antimicrobial chemotherapy.
Support for combined therapy came from animal
studies, which suggested that combination therapy
was more effective than either therapy alone against
several pathogens, including group A streptococcus
(11), pneumococcus (12), and meningococcus (13),
and some authorities recommended combined
therapy for serious infections (14,15). However, sev-
eral studies showed that combined therapy was not
more effective than antimicrobial chemotherapy
alone and that it caused significantly more side ef-
fects (16-18). Therefore, serum therapy was
abandoned because it offered no measurable advan-
tage in efficacy over chemotherapy and had
substantial disadvantages in implementation, cost,
and toxicity.
Today antibody therapy is indicated in infectious
diseases in relatively few situations, including re-
placement therapy in immunoglobulin-deficient
patients, post-exposure prophylaxis against several
viruses (e.g., rabies, measles, hepatitis A and B,
varicella), and toxin neutralization (diphtheria,
tetanus, and botulism). Ironically, the general aban-
donment of antibodies as antimicrobial agents was
followed by major advances in the technology of an-
tibody production. In 1975, hybridoma technology
provided the means to generate unlimited amounts
of monoclonal antibodies (MAbs) (19). In recent
years, major advances have been made in the tech-
niques used to generate human antibodies and
humanize murine MAbs (20).
The juxtaposition of three recent developments
makes the reintroduction of antibody-based thera-
pies an option for serious consideration. First,
because of advances in technology, human antibody
reagents can be synthesized; thus the toxicities tra-
ditionally associated with serum therapy can be
avoided. Second, the emergence of new pathogens,
the reemergence of old pathogens, and the increased
prevalence of drug-resistant microorganisms have
caused the effectiveness of existing therapeutic op-
tions to decline. Third, the difficulties involved in
treating infections in immunocompromised patients
suggest the need for adjunctive immunotherapy.
Polyclonal Sera Versus Monoclonal Antibodies
for Therapy
Immune sera contain antibodies of multiple speci-
ficities and isotypes. Problems with immune sera
include lot-to-lot variation (21), low content of spe-
cific antibodies (22), and some hazards in the
transmission of infectious diseases (23). Commer-
cially available intravenous immunoglobulin
preparations obtained from human donors differ in
their opsonic activity for common pathogens such
as Staphylococcus epidermidis, H. influenzae type
b,  S. pneumoniae, group B streptococcus, and
Escherichia coli, reflecting the characteristics of the
donor pool (22). In contrast MAbs are generated in
vitro by either hybridoma technology or recombinant
DNA techniques. MAbs are homogenous immuno-
globulins that, by definition, recognize one epitope
and have markedly higher specific activity than
polyclonal preparations. For example, 0.7 mg of two
human MAbs to tetanus toxin have the same activ-
ity as 100 to 170 mg of immune globulin (24). The
higher specific activity of MAbs may also translate
into greater therapeutic efficacy. MAbs formulations
are superior to polyclonal sera in homogeneity, con-
stancy, specific activity, and (possibly) safety. For
some infections,polyclonal preparations may be su-
perior to MAbs because MAbs contain antibodies to
multiple epitopes (i.e., they are polyvalent). How-
ever, different therapeutic MAbs can be combined
to generate polyvalent preparations composed of
antibodies with multiple specificities and isotypes.
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immunesera, antibody-based therapies for emergent
infections, if used, will likely rely primarily on MAb
technology.
Advantages of Antibody-Based Therapies
Humans can produce antibodies to practically all
existing pathogens. Antibody molecules are as-
sembled from combinations of variable gene
elements, and the possibilities resulting from com-
bining the many variable gene elements in the
germline enable the host to synthesize antibodies
to an extraordinarily large number of antigens. Dur-
ing the generation of the antibody response,
somatic mutations are introduced into immunoglo-
bulin genes, which result in higher affinity
antibodies and more diversity in specificity (25).
Thus, antibodies are, as a class, broad-spectrum
antimicrobial agents with activity against all classes
of pathogens. However, individual antibodies are
usually pathogen-specific. Pathogen-specific antimi-
crobial agents have the theoretical advantage that
they do not select for resistant organisms among
nontargeted microbes and are unlikely to produce
great disturbances in the normal host flora.
Antibody-based therapies could, in theory, be
developed against any pathogen. Although the level
of antibody immunity differs among pathogens, it
may be possible to develop useful antibody thera-
pies even if natural antibody immunity plays little
or no role in protection. Two fungi, Candida albicans
and  Cryptococcus neoformans, are pathogens for
which protective antibodies can be generated despite
uncertainty about the role of natural antibody im-
munity (26). The MAbs to C. neoformans enhance
the therapeutic efficacy of amphotericin b (27,28),
fluconazole (29), and 5-flucytosine (30) in murine
models of cryptococcosis. Therefore, uncertainty re-
garding the role of natural antibody immunity in
protecting against a given pathogen does not rule
out the existence of antibodies that may be useful in
therapy.
Microbial targets for therapeutic antibody devel-
opment are not necessarily limited to extracellular
pathogens. Although intracellular pathogens are
commonly believed to be outside the reach of anti-
body immunity, several reports have suggested that
some MAbs are active against some intracellular
microorganisms. Some IgA MAbs can neutralize in-
tracellular viruses (31), and an MAb to Toxoplasma
gondii has been reported to interfere with intracel-
lular replication of the parasite (32). It has been
proposed that intracellular virus neutralization by
IgA occurs by antibodies binding to viral proteins
and interfering with viral assembly (31). Additional
evidence for intracellular antibody activity comes
from the observation that IgG anti-DNA autoanti-
bodies can enter the cytoplasm and nucleus of living
cells (33).
Antibodies mediate antimicrobial function
through a variety of mechanisms, including inhibi-
tion of microbial attachment, agglutination, viral
neutralization, toxin neutralization, antibody-
directed cellular cytotoxicity, complement activation,
and opsonization (34). Antibodies are extremely ver-
satile antimicrobial molecules: some are active
directly against the pathogen, some neutralize the
toxic products of infection, and others enhance the
efficacy of host effector cells. Some MAbs to poliovi-
rus are neutralizing only at fever temperatures (35),
which demonstrates their ability to function at physi-
ologic extremes. The versatility of antibody-based
therapies is illustrated by the ability of digoxin-bind-
ing antibodies to reverse digoxin toxicity (36) and
recent attempts to treat septic shock by employing
MAbs that bind cytokines (37).
Human IgG has favorable pharmacokinetics for
use as an antimicrobial agent, including good tissue
penetration (38) and a half-life of about 20 days (39).
Murine MAbs have much shorter half-lives in hu-
mans, and these usually elicit human antibody
responses (40). Human-mouse chimeric antibodies
and humanized MAbs are synthetic molecules com-
posed primarily of human antibody protein
sequences that retain the antigen-binding site of the
heterologous antibody (20). Human-mouse chimeric
antibodies and humanized MAbs have longer half-
lives than the murine precursor, but their half-lives
are still much shorter than that of native human
IgG (41). This area is being intensively investigated,
and genetic engineering of antibody molecules may
be used to synthesize MAbs with longer half-lives.
Immunoglobulin therapy with human reagents
is generally well tolerated (42). Serious adverse re-
actions, including renal failure (43), aseptic
meningitis (44), and thromboembolic events (45) can
occur with high-dose (0.5 to 2  g/kg) antibody therapy.
However, antiinfective immunoglobulin therapy
with MAb preparations is unlikely to require the
high doses of immunoglobulin used to treat rheu-
matic disorders and other conditions. For ex-
ample, the heterologous immune sera used in the
preantibiotic era were effective, although they con-
tained small amounts of specific antibody. The higher
activity of MAb preparations should permit a smaller
amount of immunoglobulin proteins to be used and
thus avoid the occasional toxicity reported with high-
dose antibody therapy.204 Emerging Infectious Diseases Vol. 2, No. 3—July-September 1996
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Problems with Antibody-Based Therapies
Most antibody therapies are pathogen-specific.
This is a disadvantage in dealing with mixed infec-
tions. Mixed infection with multiple S. pneumoniae
serotypes was recognized as a cause for the failure
of serum therapy (46). For pathogens that are anti-
genically variable, one solution is to use antibody
cocktails of agents active against the most common
antigenic types. Antibody cocktails may also be de-
signed to include antibodies of different isotypes to
enhance antibody effector function. The successful
implementation of antibody-based therapies would
also require improvements in diagnostic microbiol-
ogy. In the preantibiotic era, for lobar pneumonia,
rapid protocols were developed for the isolation and
typing of pneumococci from sputum (47). Recent
advances in diagnostic microbiology, including
polymerase chain reaction and nucleic acid hybrid-
ization, could substantially shorten the time
required to establish a microbiologic diagnosis. The
narrow spectrum of antimicrobial activity that char-
acterizes antibody-based therapies is a drawback for
commercial development, however. Pathogen-spe-
cific drugs, have smaller potential markets than
broad-spectrum antimicrobial agents, and this
makes them less attractive to the pharmaceutical
industry. Conversely, the emergence of multidrug-
resistant microorganisms and new pathogens for
which no drugs exist could make pathogen-specific
drugs attractive for commercial development.
Widespread use of antibody-based therapies
could produce selective pressure on microbial popu-
lations for the emergence of antibody-resistant
variants. Antibody-resistant mutants of Borrelia
burdorferi have been produced in the laboratory (48),
and may be selected in patients who undergo anti-
body-based therapies. Microorganisms may become
resistant to antibodies by acquiring mutations that
change the antigenic site recognized by the anti-bod-
ies or by producing proteases that destroy
immunoglobulins. The IgA protease genes of N.
gonorrhoeae can be transferred between strains, and
the widespread use of antibody therapies may se-
lect for protease-producing strains (49). However,
the versatility of antibody technologies provides al-
ternatives for countering antibody-resistant strains.
For instance, new antibodies directed toward the
mutated epitope could be developed, or antibodies
that bind other antigenic targets could be
introduced. Protease-producing strains could be
countered with protease-resistant immunoglobulin
molecules generated by introducing amino acid
changes at protease cleavage sites. Alternatively,
MAbs that neutralize proteases could be incorpo-
rated into therapeutic antibody cocktails in a man-
ner analogous to the present practice of using
beta-lactamase inhibitors to increase the effective-
ness of beta-lactam antibiotics. Recognizing that the
introduction of new agents has been inevitably fol-
lowed by the emergence of resistance, researchers
could attempt to minimize the emergence of anti-
body-resistant organisms from the outset by using
cocktails of MAbs directed at multiple antigenic
targets.Combining antibody therapy with chemo-
therapy also could reduce the probability of selecting
for organisms resistant to either therapeutic modal-
ity.
Antibodies are more effective in preventing in-
fection than in treating established infection.
Antibody-based therapies have been most useful
when administered early in the course of disease:
serum therapy for pneumococcal pneumonia was
most effective if  serum was administered within 3
days of the onset of clinical symptoms (6). Because
antibodies are proteins, therapy for invasive infec-
tions is likely to require systemic administration.
This is a serious disadvantage in developing coun-
tries where access to medical care is limited. For
enteric pathogens, oral antibody administration may
be most effective (50,51). Efforts to develop MAbs
for cancer therapy have run into unexpected
pharmacologic problems (38,40). The finding that
MAb uptake by tumors is partially dependent on
antigen expression in the tumor (40) suggests that
MAb uptake by infected tissues could depend on
microbial antigen expression at the site. The same
problems may be found when antibody penetrates
tumors.
Antibodies can, in principle, elicit neutralizing
antibody, allergic responses, or both. Administering
rodent MAbs to patients elicits human antibodies
to the rodent MAb (52). Antibody therapies against
emergent pathogens, if attempted, are likely to use
human, human-animal chimeric, or humanized an-
tibodies. Mouse-human chimerics and humanized
antibodies are less immunogenic than heterologous
antibodies (41,53,54); therefore, the likelihood that
the patient will mount a neutralizing antibody re-
sponse to the therapeutic antibody may be reduced.
Nevertheless, antiidiotypic responses have been ob-
served in patients receiving humanized antibody
therapy (54). The clinical importance of such
antiidiotypic responses is uncertain. Many infections
are single life-threatening episodes in the life of a
person, and the occurrence of antiidiotypic antibod-
ies following therapy may require repeated or
long-term antibody administration.
Antibodies are largely excluded from the centralVol. 2, No. 3—July-September 1996 Emerging Infectious Diseases 205
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Figure 2. Schematic illustration of the major events in the development of serum therapy for pneumococcal pneumonia
and meningococcal meningitis. For pneumococcal pneumonia, considerable uncertainty existed regarding the useful-
ness of serum therapy in the decades following the demonstration that immune sera could transfer protection to
animals. However, the discovery that type-specific serum necessary for efficacy, followed by extensive clinical trials, led
to the general acceptance of serum therapy for pneumococcal pneumonia in the late 1920s. For meningococcal menin-
gitis, the antisera generated against the strains prevalent in the early 1900s proved to be effective in therapy. However,
the efficacy of serum therapy in later epidemics of meningococcal meningitis was significantly lower, leading to uncer-
tainty about the value of serum therapy for this infection (16).
nervous system by the blood-brain barrier. Never-
theless, antibody treatment of brain infections is
feasible. In some brain infections, the blood-brain
barrier is more permeable to serum components
because of inflammation, and systemic antibody
therapy was used successfully to meningococcal
meningitis (55). If antibody penetration to brain tis-
sue is a problem, two alternatives exist. First,
antibodies can be administered directly into the sub-
arachnoid space (as was done for the treatment of
meningococcal meningitis in the preantibiotic era)
(15,56). Second, antibody molecules can be engi-
neered for enhanced brain penetration by altering
their charge (57) or by linking them to proteins that
cross the blood-brain barrier (58).
Antibody therapies are also costly to develop and
expensive for the patient. For example, antibody
prophylaxis for cytomegalovirus infections can cost
several thousand dollars per patient (59). To be cost-
effective, antibody-based therapies would have to
provide a clear benefit over existing therapy. For
emerging pathogens for which no therapy is avail-
able, the cost of antibody therapies may be
justifiable, depending on the potential for death, ill-
ness, and long-term consequences of the infection.
In the long run, advances in antibody production
and improvements in technology may greatly lower
costs and make antibody-based therapy more com-
petitive with antimicrobial chemotherapy.
Historical Perspective on the Development of
Antibody Therapies
In recent years, considerable interest has been
expressed in using antibody-based therapies to treat
septic shock (60). Unfortunately, MAbs to endotoxin
have not been as effective in clinical trials as antici-
pated (61,62), and this has dampened some of the
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enthusiasm for MAb therapies. The development of
serum therapy for S. pneumoniae also encountered
considerable difficulties in the preantibiotic era.
The Klemperers demonstrated that immune se-
rum protected rabbits in 1891 (63), but reliable
antibody therapies for pneumococcal pneumonia
were not available until the 1920s (Figure 2). Trans-
lating the laboratory finding that immune sera
protected rabbits against experimental pneumococ-
cal infection to the successful use of serum therapy
for lobar pneumonia in humans required extensive
basic and clinical research. At the laboratory bench,
developing antibody therapy for pneumococcal pneu-
monia required the discovery that antigenic
variation existed among pneumococcal strains, that
only type-specific sera provided protection, that cer-
tain vaccination schedules were necessary to elicit
good antibody responses, the ability to standardize
the serum potency (by the mouse protection test),
and improved antibody purification techniques (6).
At the bedside, implementing successful serum
therapy required learning when and how to give
serum, managing the side effects of serum therapy,
and developing rapid protocols for recovering pneu-
mococci from sputum for serum typing (64). The
mouse protection test reduced but did not eliminate
the problems of lot-to-lot variation in serum efficacy
(21). The development and perfection of antibody
therapies for pneumococcus contributed important
research findings, which led to major discoveries in
immunology (65). The high death rate for meningo-
coccal meningitis also led to the rapid development
of serum therapy (6). In the early 1900s, serum
therapy markedly reduced the death rate of menin-
gococcal epidemics, possibly because of antigenic
changes in the pathogen (6). The lengthy time re-
quired for the development of serum ther-
apy for pneumococcus, the variable efficacy of
antimeningococcal sera (depending on the epidemic),
and the more recent difficulties encountered in de-
veloping MAb therapy for septic shock suggest that
developing antibody-based therapies for emergent
pathogens will require extensive preclinical and
clinical testing.
Other Antibody-Based Strategies Against
Emerging Pathogens
Vaccines that elicit protective antibody immunity
could be used to protect against emergent patho-
gens. A polysaccharide-protein conjugate vaccine is
being developed (66) against C. neoformans. This
vaccine elicits protective antibodies in mice (67), and
it is hoped that vaccination will result in the pro-
duction of effective anti-cryptococcal antibodies to
prevent disease in patients at risk. The conjugate
vaccine against C. neoformans is intended to elicit
protective antibody immunity, even though the role
of natural antibody immunity in protection against
cryptococcosis is uncertain (26). Newer vaccines
against common pathogens could help limit the
spread of drug-resistant microorganisms. Dissemi-
nation of penicillin-resistant pneumococci has been
associated with infection and carriage by young
children among whom the current 23-valent pneu-
mococcal polysaccharide vaccine is ineffective in
inducing protective immunity (4). However, the ef-
fectiveness of polysaccharide-protein conjugate
vaccine to H. influenzae type b suggests that a simi-
lar conjugate vaccine to S. pneumoniae, if available,
could effectively abort childhood infection with
antibiotic-resistant pneumococci and thereby limit
the spread of these strains (4).
Future Directions
Immunoglobulins are an extremely versatile
class of antimicrobial proteins that can be used to
prevent and treat emerging infectious diseases. An-
tibody therapy has been effective against a variety
of diverse microorganisms. The historical record
clearly documents both the usefulness and the diffi-
culties in developing and implementing passive
antibody therapies. The experience with serum
therapy for pneumococcal pneumonia and menin-
gococcal meningitis suggests that extensive basic
and clinical research is essential for the successful
implementation of antibody therapy. Given the mul-
titude of pathogens, the pathogen-specific nature of
antibody therapies, and the costs of developing and
using antibody therapies, the development of such
therapies for most pathogens at present, would be
impractical. However, for selected pathogens, anti-
body-based therapies could provide new therapeutic
options. Opportunities for the development of anti-
body-based strategies include 1) pathogens for which
there is no available antimicrobial therapy (e.g., C.
parvum and vancomycin-resistant enterococcus); 2)
pathogens that affect primarily immuno-compro-
mised patients in whom antimicrobial therapy is not
very effective (e.g., invasive fungal infections); 3)
pathogens for which drug-resistant variants are rap-
idly spreading (e.g., Pseudomonas aeruginosa [68]);
and 4) highly virulent pathogens for which few ef-
fective antimicrobial agents are available (e.g.,
methicillin-resistant S. aureus).Vol. 2, No. 3—July-September 1996 Emerging Infectious Diseases 207
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